NCT03251443 is a Phase 2 clinical trial of Apatinib in Intrahepatic Cholangiocarcinoma, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT03251443?

NCT03251443 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT03251443?

Interventions in NCT03251443: Apatinib.

What condition does NCT03251443 study?

NCT03251443 studies Intrahepatic Cholangiocarcinoma, Second-line Treatment.

Is NCT03251443 still recruiting?

NCT03251443 is currently completed. Last updated 2 December 2020.

Last reviewed 2020-12-02 · How we verify

NCT03251443

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Completed Phase 2 Last updated 2 December 2020

What this trial tests

Phase 2 trial testing Apatinib in Intrahepatic Cholangiocarcinoma in 34 participants. Completed in 8 May 2019.

Timeline

8 August 2017

Primary endpoint
8 March 2019

8 May 2019

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	8 August 2017
Primary completion	8 March 2019
Estimated completion	8 May 2019
Sites	1 location across China

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →

Conditions studied

Intrahepatic Cholangiocarcinoma — all drugs for Intrahepatic Cholangiocarcinoma →
Second-line Treatment — all drugs for Second-line Treatment →

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with Intrahepatic Cholangiocarcinoma or Second-line Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the efficacy and safety of second-line treatment of apatinib in advanced intrahepatic cholangiocarcinoma patients and evaluate drug safety, progression free and overall survival. The primary endpoint of this study is objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Tumor Microenvironment for Cancer Therapy.
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. · · 2019 · cited 865× · PMID 30781344 · DOI 10.3390/ijms20040840
Progress in the treatment of solid tumors with apatinib: a systematic review.
Zhao D, Hou H, Zhang X. · · 2018 · cited 52× · PMID 30050305 · DOI 10.2147/ott.s172305
Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type.
Shiao MS, Chiablaem K, Charoensawan V, Ngamphaiboon N, et al · · 2018 · cited 18× · PMID 30158952 · DOI 10.3389/fgene.2018.00309
Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
Zhang G, Gong S, Pang L, Hou L, et al · · 2021 · cited 14× · PMID 34012920 · DOI 10.3389/fonc.2021.659217
Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma.
Mao J, Yang X, Lin J, Yang X, et al · · 2021 · cited 13× · PMID 33532001 · DOI 10.7150/jca.53482
Tumor microenvironment and immunology of cholangiocarcinoma.
Cadamuro M, Fabris L, Zhang X, Strazzabosco M. · · 2022 · cited 8× · PMID 39301518 · DOI 10.20517/2394-5079.2021.140
Emerging Therapies in Management of Cholangiocarcinoma.
Speckart J, Rasmusen V, Talib Z, GnanaDev DA, et al · · 2024 · cited 8× · PMID 38339363 · DOI 10.3390/cancers16030613
Cholangiocarcinoma: the quest for a second-line systemic treatment.
Vienot A, Neuzillet C. · · 2019 · cited 7× · PMID 35117107 · DOI 10.21037/tcr.2018.10.05

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other recruiting trials for Intrahepatic Cholangiocarcinoma

Currently open trials in the same condition.

NCT06990659 — Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) · NA · recruiting
NCT06910722 — Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy · NA · recruiting
NCT07169734 — A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06664021 — Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperativ · Phase 2 · recruiting
NCT06505486 — GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03251443 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 2 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03251443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing